Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA ...

Various respiratory illnesses as well as the Norovirus, otherwise known as the stomach flu, are circulating in the Chippewa Valley. “We’ve seen an increase in COVID-19, RSV, influenza, as well as ...

So, what vaccines should we get as adults? There are a lot, but we will focus on adult respiratory illnesses since these have the highest impact on the adult population. Some vaccines are only ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (the ...

State health officials are seeing the highest numbers all winter lately with approximately 9.5 of the 600 tests for RSV ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.